New hope for lung cancer patients Who've tried everything?
NCT ID NCT06879717
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a new drug called roginolisib combined with two other drugs (dostarlimab and docetaxel) in 45 adults with advanced non-squamous lung cancer that has worsened after standard treatments. The main goals are to see if the combo is safe and whether it reduces certain immune cells in the blood. It is an early-stage study, so the focus is on safety and immune response rather than cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
roginolisib (tablet), dostarlimab (IV infusion), docetaxel (IV infusion)
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta VZW
Roeselare, 8800, Belgium
-
Antwerp University Hospital
Antwerp, 2650, Belgium
-
Hospital Universitari Son Espases
Palma, 07120, Spain
-
Hospital Universitario y Politécnico La Fe
Valencia, 46026, Spain
-
Humanitas University, Department of Medical Oncology
Rozzano, Milan, 20072, Italy
-
Institut Català d'Oncologia Hospitalet
Barcelona, 08908, Spain
-
Istituto Romagnolo per lo studio dei Tumori "Dino Amadori"
Meldola, Forlì-Cesena, 47014, Italy